Given the recent use of palbociclib in clinical trials for NSCLC patients, understanding the functional consequences of CDK4/6 inhibition on cancer cell metabolism are important for identifying potential combination therapies to improve patient outcome. This evidence concerns the gene CDK4 and cancer.